表紙
市場調査レポート - 219637

インフルエンザワクチンの世界市場の分析 (2020年まで)

Global Influenza Vaccine Market Outlook 2020

発行 RNCOS E-Services Pvt. Ltd.
出版日 ページ情報 英文 90 Pages
電子版即納可
価格
Back to Top
インフルエンザワクチンの世界市場の分析 (2020年まで) Global Influenza Vaccine Market Outlook 2020
出版日: 2015年04月01日 ページ情報: 英文 90 Pages
概要

H1N1型インフルエンザの流行以来、世界各国は予防接種活動に積極的に取り組んでいます。過去のパンデミックで拡散したウイルスは、今後も世界各地で流行し続ける見込みで、それがその時点で流行しているウイルスへの対応を滞らせる一因となっています。さらに、世界の総人口の大半がインフルエンザ関連の諸問題の影響を蒙っています。逆に言えば、未開拓かつ急成長中の市場が存在しているわけで、これが新規参入企業に巨大な潜在的機会をもたらしています。現在、季節性インフルエンザ向けワクチンが認証されたことや、最新型アジュバンドが上市されたことから、インフルエンザワクチン市場は急速に成長しており、2014〜2020年の年平均成長率 (CAGR) は5.5%に達する見通しです。地域別にみると、巨大な人口ベースやワクチン接種率の低さなどを反映して、中国・インドなどの新興国が注目を集めています。

当レポートでは、世界のインフルエンザワクチン市場に関する詳細な分析を行っており、疾患および治療法の概要や、市場の将来予測 (今後7年間分) 、地域別の詳細動向、主要企業のプロファイルおよびパイプライン製品といった情報を取りまとめてお届けします。

第1章 アナリストの見解

第2章 調査手法

第3章 インフルエンザワクチン:イントロダクション

第4章 世界のインフルエンザワクチン市場の将来展望

  • 市場の現状と将来展望
  • 主要な上市済みワクチン
    • Fluzone/Vaxigrip
    • FluMist
    • FluarixおよびFlulaval
    • Anflu
    • Fluvax/Afluria
    • FlucelvaxおよびFluvirin

第5章 主な地域市場

  • 米国
  • 欧州
  • 新興国市場
    • 中国
    • インド
  • その他の地域 (ROW)
    • オーストラリア
    • 日本

第6章 世界のインフルエンザワクチン市場:パイプライン分析

第7章 世界のインフルエンザワクチン市場:価格分析

第8章 競合評価

  • Sanofi
    • 事業内容
    • 財務概要
    • インフルエンザワクチン事業
  • GlaxoSmithKline Plc (GSK)
  • CSL Ltd
  • AstraZeneca Plc
  • Sinovac Biotech
  • Serum Institute of India

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Influenza vaccines are considered as an optimum source of prevention from diseases caused by flu virus. Since the H1N1 pandemic, worldwide authorities have started to adopt proactive approach in the vaccination process. Virus of previous pandemics are still circulating in the environment and in the coming future, they may be classified as strains to be updated in seasonal vaccines. Moreover, a large chunk of global population is affected by influenza-related problems. In such a scenario, huge opportunity lies for industry participants to tap the fast growing market.

In 2014, the global market for influenza vaccines has shown tremendous growth backed by certain key prominent factors. Approval of new seasonal influenza vaccines by authorities and significant developments in adjuvant technology are going to impact the market in a positive manner. The global volume sales of influenza vaccine is expected to grow at a CAGR of 5.5% during the forecasted period, i.e., 2014-2020.

Emerging markets predominantly is the main focus in the global influenza vaccine market landscape. Vast population base together with significantly low vaccination coverage are the prominent factors that will drive the future growth in countries, such as China and India. Market players have already started devising strategies including agreements with domestic manufacturers/distributors to increase their presence in China. India, on the contrary, is engaged in the collection of data that may facilitate in the development of flu vaccination strategies among the population.

In our report "Global Influenza Vaccine Market Outlook 2020", we have segmented the global influenza vaccine market based on the major vaccine in the market and volume and value sales for each vaccine have been analyzed. Followed by this, important geographies have been highlighted along with their current and future markets outlook till 2020. The report also covers advanced stage pipeline analysis of key players, which list down the influenza vaccines already in Phase III trials.

In the end, various key players have been enlisted. Our team has analyzed each company's financial performance along with its vaccine portfolio and pipeline that will help the reader to better position his company vis-à-vis competition.

Table of Contents

1. Analyst View

2. Research Methodology

3. Influenza Vaccine - Introduction

4. Global Influenza Vaccine Market Outlook 2020

  • 4.1 Current Market Overview and Future Outlook
  • 4.2 Major Marketed Vaccines
    • 4.2.1 Fluzone/Vaxigrip
    • 4.2.2 FluMist
    • 4.2.3 Fluarix and Flulaval
    • 4.2.4 Anflu
    • 4.2.5 Fluvax/Afluria
    • 4.2.6 Flucelvax and Fluvirin

5. Key Geographical Market

  • 5.1 US
  • 5.2 Europe
  • 5.3 Emerging Markets
    • 5.3.1 China
    • 5.3.2 India
  • 5.4 Rest of the World
    • 5.4.1 Australia
    • 5.4.2 Japan

6. Global Influenza Vaccine Market: Pipeline Analysis

7. Global Influenza Vaccine Market: Pricing Analysis

8. Competitive Assessment

  • 8.1 Sanofi
    • 8.1.1 Business Description
    • 8.1.2 Financial Overview
    • 8.1.3 Influenza Vaccine Business
  • 8.2 GlaxoSmithKline Plc (GSK)
    • 8.2.1 Business Overview
    • 8.2.2 Financial Overview
    • 8.2.3 Influenza Vaccine Business
  • 8.3 CSL Ltd
    • 8.3.1 Business Overview
    • 8.3.2 Financial Overview
    • 8.3.3 Influenza Vaccine Business
  • 8.4 AstraZeneca Plc
    • 8.4.1 Business Overview
    • 8.4.2 Financial Overview
    • 8.4.3 Influenza Vaccine Business
  • 8.5 Sinovac Biotech
    • 8.5.1 Business Overview
    • 8.5.2 Financial Overview
    • 8.5.3 Influenza Vaccine Business
  • 8.6 Serum Institute of India
    • 8.6.1 Business Overview
    • 8.6.2 Influenza Vaccine Business

List of Figures:

  • Figure 4-1: Global - Production Capacity and Production of Influenza Vaccine (Million Doses), 2009 & 2011
  • Figure 4-2: Global - Influenza Vaccine Sales (Million Doses), 2014 & 2020
  • Figure 4-3: Global - Influenza Vaccine Market (Billion US$), 2014-2020
  • Figure 4-4: Global - Influenza Vaccine Market by Players (%), 2014
  • Figure 4-5: Global - Fluzone/Vaxigrip Sales (Million US$), 2010-2014
  • Figure 4-6: Global - FluMist Sales (Million US$), 2010-2014
  • Figure 4-7: Global - Fluarix and FluLaval Sales (Million US$), 2010-2014
  • Figure 4-8: Global - Anflu Sales (Million Doses), 2010-2013
  • Figure 4-9: Global - Anflu Sales (Million Doses), 2010-2013
  • Figure 4-10: Global - Afluria/Fluvax Sales (Million US$), 2012-2014
  • Figure 4-11: Global - Flucevax and Fluvirin Sales (Million US$), 2012-2014
  • Figure 5-1: Global - Influenza Vaccine Market by Region (%), 2014
  • Figure 5-2: US - Influenza Vaccine Sales (Million Doses), 2009-10 to 2014-15
  • Figure 5-3: US - Influenza Vaccine Market by Players (%), 2014
  • Figure 5-4: US - Influenza Vaccine Market (Billion US$), 2014-2020
  • Figure 5-5: Europe - Influenza Vaccine Market by Players (%), 2014
  • Figure 5-6: Europe - Influenza Vaccine Market (Million US$), 2014-2020
  • Figure 5-7: Europe - Seasonal Influenza Vaccination Coverage in Older Age Group by Country (%), 2011-12 & 2012-13
  • Figure 5-8: Emerging Markets - Influenza Vaccine Market by Players (%), 2014
  • Figure 5-9: Emerging Markets - Influenza Vaccine Market (Million US$), 2014-2020
  • Figure 5-10: Rest of the World - Influenza Vaccine Market (Million US$), 2014-2020
  • Figure 8-1: Sanofi - Breakup of Total Revenues by Business Segment (%), 2014
  • Figure 8-2: Sanofi Pasteur - Breakup of Vaccine Segment by Type (%), 2014
  • Figure 8-3: Sanofi Pasteur - Breakup of Total Influenza Vaccine Revenues by Geography (%), 2014
  • Figure 8-4: GlaxoSmithKline Plc - Breakup of Total Revenues by Business Segment (%), 2014
  • Figure 8-5: GlaxoSmithKline Plc - Breakup of Vaccine Segment by Type (%), 2014
  • Figure 8-6: GlaxoSmithKline Plc - Breakup of Total Influenza Vaccine Revenue by Geography (%), 2014
  • Figure 8-7: CSL Ltd - Breakup of Total Revenues by Business Segment (%), 2014
  • Figure 8-8: CSL Ltd - Breakup of bioCSL Revenues by Product Type (%), 2014
  • Figure 8-9: AstraZeneca Plc - Breakup of Total Revenues by Business Segment (%), 2014
  • Figure 8-10: AstraZeneca Plc - Breakup of Infection Segment by Type (%), 2014
  • Figure 8-11: AstraZeneca Plc - Breakup of Total Influenza Vaccine Revenues by Geography (%), 2014
  • Figure 8-12: Sinovac Biotech - Breakup of Vaccine by Type (%), 2013

List of Tables:

  • Table 5-1: US - Major Influenza Vaccines & Manufacturers (2014-15)
  • Table 5-2: Percentage of People in the US Who Received Influenza Vaccine (2013-14)
  • Table 5-3: Number of Pediatric Deaths in US Flu Season (2005-06 to 2014-15)
  • Table 5-4: US - Seasonal Influenza Vaccination Coverage by Group (%), 2011-12 to 2013-14
  • Table 5-5: Europe - Major Influenza Vaccines & Manufacturers (2014-15)
  • Table 5-6: China - Vaccine Classification
  • Table 5-7: Australia - Major Influenza Vaccines & Manufacturer (2014-15)
  • Table 6-1: Influenza Vaccine - Pipeline Analysis, 2014
  • Table 7-1: Major Influenza Vaccines Cost/Dose (US$) for 2015-16 Season
  • Table 8-1: Sanofi - Key Financials (Million US$), 2012-2014
  • Table 8-2: Influenza Vaccines Offered by Sanofi Pasteur (2014)
  • Table 8-3: GlaxoSmithKline Plc - Key Financials (Million US$), 2012-2014
  • Table 8-4: Influenza Vaccines Offered by GlaxoSmithKline Plc (2014)
  • Table 8-5: CSL Ltd. - Key Financials (Million US$), 2012-2014
  • Table 8-6: CSL Influenza Vaccine Portfolio before Merger
  • Table 8-7: CSL Influenza Vaccine Portfolio after Merger
  • Table 8-8: AstraZeneca Plc - Key Financials (Million US$), 2012-2014
  • Table 8-9: Influenza Vaccines Offered by AstraZeneca Plc (2014)
  • Table 8-10: Sinovac Biotech - Key Financials (Million US$), 2011-2013
  • Table 8-11: Influenza Vaccines Offered by Sinovac Biotech (2014)
Back to Top